Cargando…

Vidjil add‐on for MRD quantification of samples processed using the EuroClonality‐NGS protocol

Assessment of minimal residual disease in acute lymphoblastic leukemia by immune repertoire NGS requires spiking CDR3 sequences at known quantities into the patient's sample. Recently, the EuroClonality‐NGS group released one of the most comprehensive protocols for this purpose. ARResT/Interrog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giusti, Guilherme Navarro Nilo, Ribeiro, Antonio Vítor, Jotta, Patrícia Yoshioka, Thonier, Florian, Yunes, José Andrés, Meidanis, João
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435716/ https://www.ncbi.nlm.nih.gov/pubmed/37601854 http://dx.doi.org/10.1002/jha2.749

Ejemplares similares

Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Clonotype definitions for immunogenetic studies: proposals from the EuroClonality NGS Working Group
por: Sofou, Electra, et al.
Publicado: (2023)

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
por: Knecht, Henrik, et al.
Publicado: (2019)

Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
por: Brüggemann, Monika, et al.
Publicado: (2019)

Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS
por: Scheijen, Blanca, et al.
Publicado: (2019)

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations
por: Langerak, A W, et al.
Publicado: (2012)

Vidjil: A Web Platform for Analysis of High-Throughput Repertoire Sequencing
por: Duez, Marc, et al.
Publicado: (2016)

Correction: Vidjil: A Web Platform for Analysis of High-Throughput Repertoire Sequencing
por: Duez, Marc, et al.
Publicado: (2017)

A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonality: A Comparative Study from the EuroClonality Consortium
por: Armand, Marine, et al.
Publicado: (2019)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?
por: Cengiz Seval, Guldane, et al.
Publicado: (2022)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
por: Loo, Sun, et al.
Publicado: (2022)

P1263: A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES
por: Hebert, L., et al.
Publicado: (2022)

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
por: Li, Yonghong, et al.
Publicado: (2023)

PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC.
por: Sánchez-Redondo, Noemí Álvarez, et al.
Publicado: (2023)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

PB2167: NGS CLONALITY TESTING FOR A DIFFERENTIAL DIAGNOSIS OF MYCOSIS FUNGOIDES
por: Sidorova, Y., et al.
Publicado: (2022)

Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing
por: Glenn, Sean T., et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

The Return of Fiscal Policy and the Euro Area Fiscal Rule
por: Constâncio, Vítor
Publicado: (2020)

Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics
por: Petrackova, Anna, et al.
Publicado: (2019)

P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)
por: Zamanillo, Irene, et al.
Publicado: (2023)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

A high-throughput optomechanical retrieval method for sequence-verified clonal DNA from the NGS platform
por: Lee, Howon, et al.
Publicado: (2015)

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter's Transformation and CLL/SLL
por: Kadkol, Shrihari S., et al.
Publicado: (2021)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

Quantification of HTLV-1 Clonality and TCR Diversity
por: Laydon, Daniel J., et al.
Publicado: (2014)

P383: THE NEXT-GENERATION SEQUENCING (NGS) BASED MRD ASSESSMENT COULD BETTER PREDICT RELAPSE THAN MULTIPARAMETER FLOW CYTOMETRY (MFC) IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Yan, Nan, et al.
Publicado: (2023)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

NP-MRD: the Natural Products Magnetic Resonance Database
por: Wishart, David S, et al.
Publicado: (2021)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

The price of the Euro /
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_fu6f8m1sunfh83dcqe9ajvojk2